La Jolla Pharmaceutical Company
Table of Contents


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549


FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 16, 2003

La Jolla Pharmaceutical Company


(Exact Name of Registrant as Specified in Charter)
         
Delaware   0-24274   33-0361285

 
 
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
     
6455 Nancy Ridge Drive, San Diego, California   92121

 
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 452-6600

N/A


(Former Name or Former Address, if Changed Since Last Report)


 


TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1


Table of Contents

Item 5. Other Events and Required FD Disclosure.

     On June 16, 2003, the Company issued a press release announcing, among other matters, the health-related quality of life results from the Riquent™ Phase 3 trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

  (c)   Exhibits. The following exhibits are filed with this report on Form 8-K:
     
Exhibit    
Number   Description of Exhibit

 
99.1   Press Release

 


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
  LA JOLLA PHARMACEUTICAL COMPANY
 
Date: June 16, 2003 By: /s/ Steven B. Engle
   
    Steven B. Engle
    Chairman and Chief Executive Officer

 


Table of Contents

EXHIBIT INDEX

     
Exhibit    
Number   Description of Exhibit

 
99.1   Press Release